Merck Drug Pipeline

Merck’s clinical portfolio reflects a major pharmaceutical company with extensive research and development activity. The company currently has 222 active clinical trials, part of a larger history of 1355 trials registered since 2008. These active trials span a range of development phases, with 74 in Phase 1, 86 in Phase 2, and 101 in Phase 3, plus no active Phase 4 trials. Merck’s research is distributed across 17 therapeutic areas, but is heavily concentrated in oncology, which accounts for 171 active trials, or 77% of the total active programs. Within oncology, the leading indications are advanced solid tumors (47 active trials, including 20 in Phase 3), non-small cell lung cancer (NSCLC) (25 active trials, including 19 in Phase 3), Non-Hodgkin Lymphoma (15 active trials, including 5 in Phase 3), Bladder Cancer (11 active trials, including 4 in Phase 3), and Melanoma (7 active trials, including 3 in Phase 3). Beyond oncology, other areas of focus include infectious disease (13 active trials), immunology (8 active trials), metabolic disorders (6 active trials), cardiovascular disease (6 active trials), and central nervous system disorders (2 active trials). The substantial number of Phase 3 trials, particularly within oncology, suggests a pipeline with numerous near-term milestones.